1Stenmark KR.McMurtry IF. Vascular remodeling versus vasoconstriction in chronic hypoxic pulmonary hypertension: A time for reappraisal. Cir Res, 2005,97:95-98.
23rd World PAH Symposium. Pulmonary arterial hypertension: epidemiology, pathobiology, assessment and therapy. J Am Coll Cardiol, 2004,43 : 1-90.
3Humbert M, Sit bon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med, 2004,351:1425-1436.
4McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension:the impact of epoprostenol therapy. Circulation, 2002,106:1477-1482.
5Simonneau G,Barst RJ ,Galie N,et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A double-blind randomized controlled trial. Am J Respir Crit Care Med, 2002,165:800-804.
6Galie N, Humbert M, Vachiery J L, et al. Effects of beraprost sodium,an oral prostacyclin analogue,in patients with pulmonary arterial hypertension:a randomized double-blind placebocontrolled trial. J Am Coll Cardiol, 2002,39:1496-1502.
7Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med, 2002,347 : 322-329.
8Sablotzki A, Hentschel T, Hofmann S, et al. Inhaled aerosolized iloprost in the evaluation of heart transplant candidates-experiences with 45 cases. J Clin Anesth, 2006,18:108-113.
9Schermuly RT, Kreisselmeier KP ,Ghofrani HA, et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med, 2004,169:39-49.
10Galie N, Ghofrani HA, Robyn AT J, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med, 2005,353,2148-2160.
10Sablotzki A, Hent schel T, Hofmann S ,et al. Inhaled aerosolized iloprost in t he evaluation of heart t ransplant candidates -experiences with 45 cases. J Clin Anesth,2006,18 : 1082113.
